Yu M, Bardia A, Aceto N, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 2014;345(6193):216-20. doi:10.1126/science.1253533
Qin Y, McAllister SS. SPSB1 may have MET its match during breast cancer recurrence. Cancer Discov. 2014;4(7):760-1. doi:10.1158/2159-8290.CD-14-0505
Wilkerson MD, Cabanski CR, Sun W, et al. Integrated RNA and DNA sequencing improves mutation detection in low purity tumors. Nucleic Acids Res. 2014;42(13):e107. doi:10.1093/nar/gku489
Yamamoto S, Wu Z, Russnes HG, et al. JARID1B is a luminal lineage-driving oncogene in breast cancer. Cancer Cell. 2014;25(6):762-77. doi:10.1016/j.ccr.2014.04.024
Moody SE, Schinzel AC, Singh S, et al. PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. Oncogene. 2015;34(16):2061-71. doi:10.1038/onc.2014.153
Duan Q, Flynn C, Niepel M, et al. LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures. Nucleic Acids Res. 2014;42(Web Server issue):W449-60. doi:10.1093/nar/gku476
Li Q, Stram A, Chen C, et al. Expression QTL-based analyses reveal candidate causal genes and loci across five tumor types. Hum Mol Genet. 2014;23(19):5294-302. doi:10.1093/hmg/ddu228